

# Catalytic Asymmetric *endo*-Selective [3+2] Cycloaddition Reactions of Schiff Bases of $\alpha$ -Aminophosphonates with Olefins Using Chiral Metal Amides

Yasuhiro Yamashita, Liang Cheng Nam, Mark J. Dutton, Susumu Yoshimoto, and Shū Kobayashi\*

Department of Chemistry, School of Science, The University of Tokyo, Hongo, Bunkyo-ku, Tokyo  
113-0033, Japan

## Electronic Supplementary Information

### General Experimental Procedures

All reactions were conducted in flame-dried glassware with magnetic stirring. Reaction temperatures refer to external bath temperatures. Specific rotations were recorded on JASCO P-2100 polarimeter. IR Spectra were recorded as neat between NaCl plates on JASCO FT/IR-4200 spectrometer. Selected bands ( $\nu_{\text{max}}$ ) reported herein. All NMR spectra were recorded on JEOL JNM-ECX400, JNM-ECA500 and JNM-ECX600 spectrometers in chloroform-d. All signals are reported in parts per million (ppm) with reference to tetramethylsilane as the internal standard at 0 ppm ( $^1\text{H}$ ) and 77.0 ppm ( $^{13}\text{C}$ ); 85% phosphoric acid as the internal standard at 0 ppm ( $^{31}\text{P}$ ). Data is reported as s (singlet), d (doublet), t (triplet), q (quartet) and m (multiplet), with coupling constants reported to nearest 0.1 Hz.  $J$  refers to proton-proton coupling unless otherwise stated. High resolution mass spectra were recorded on JEOL JMS-T100TD spectrometer (DART). Solvents used for reactions were distilled under argon as specified – Et<sub>2</sub>O, THF, toluene, mesitylene, were distilled from sodium benzophenone ketyl; CH<sub>2</sub>Cl<sub>2</sub> was distilled from calcium hydride; BTF and xylenes were distilled and dried over molecular sieves followed by freeze-pump-thaw method. Silver triflate (AgOTf), copper(I) triflate  $\frac{1}{2}$ -toluene complex (CuOTf• $\frac{1}{2}(\text{CH}_3\text{C}_6\text{H}_5)$ ), lithium dimethyl amide (LiNMe<sub>2</sub>), lithium diisopropylamide (LDA), lithium tetramethylpiperidine (LiTMP) were purchased from Aldrich Co. Ltd. and used without purification; potassium hexamethyldisilazane (KHMDS) was purchased from Aldrich Co. Ltd. and purified by sublimation; triphenylphosphine (PPh<sub>3</sub>) was purchased from Wako Pure Chemical Industries Ltd. and recrystallised prior to use; diethylamine (HNEt<sub>2</sub>), bis(trimethylsilyl)amine (H-HMDS), 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU), triethylamine (NET<sub>3</sub>) were purchased from Wako Pure Chemical Industries Ltd. and Tokyo Chemical Industry

Co. Ltd. and distilled prior to use. Ligands were purchased from or supplied by commercial suppliers (Strem Chemicals Inc., Aldrich Co. Ltd., Tokyo Chemical Industry Co. Ltd.) and used as received. Fesulphos (**L5**) was synthesised according to the literature<sup>1)</sup> and characterised by NMR. Dipolarophiles (**2a-2e**) were purchased from commercial suppliers (Wako Pure Chemical Industries Ltd., Tokyo Chemical Industry Co. Ltd.) and purified by distillation (liquids) or recrystallization (solids) prior to use. Schiff bases (**1a-1l**) were synthesised according to the literature.<sup>2)</sup> Thin layer chromatography was performed on pre-coated silica gel 60 glass-backed plates and visualized under UV (254 nm) and/or staining by potassium permanganate followed by gentle heating with a heat gun. Preparative thin layer chromatography was performed on glass plates coated with Wakogel B-5F. High performance liquid chromatography was carried out on Shimadzu LC10ATvp or LC-20AB (liquid chromatograph), Shimadzu SPD-M20A (photo diode array detector) or SPD-10Avp (UV detector).

### [3+2] Cycloaddition of $\alpha$ -Aminophosphonate Schiff Bases

#### Typical Procedure for [3+2] Cycloaddition by CuHMDS:


To a dried 5 mL microwave vial, KHMDS (4.0 mg, 0.020 mmol), CuOTf•½(CH<sub>3</sub>C<sub>6</sub>H<sub>5</sub>) (5.7 mg, 0.022 mmol) and (*R*)-Fesulphos **L5** (10.1 mg, 0.022 mmol) was added in the glovebox under Ar atmosphere and sealed with a rubber septum. Dry mesitylene (1 mL) was added and the mixture was allowed to stir until all the solids have dissolved. It was then stirred at 40 °C for 1 hour and transferred to a 25 °C water bath. To the catalyst mixture, Schiff base **1a** (102.1 mg, 0.40 mmol), methyl acrylate **2a** (45 µL, 0.50 mmol), H-HMDS (4.2 µL, 0.020 mmol) was transferred *via* cannula by dry mesitylene (1 mL). The mixture was stirred at 25 °C for 48 hours. The reaction was quenched with saturated NH<sub>4</sub>Cl (3 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 x 15 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated *in vacuo*. The crude sample was purified by preparative TLC (Et<sub>2</sub>O/MeOH: 200/1) to afford the desired product. The enantiomeric excess of the product was analysed by HPLC. Absolute configuration of **3aa** was confirmed by X-ray crystallographic analysis of a single crystal (CCDC number: 1409067).<sup>3)</sup> The absolute configurations of the other products were determined by analogy to **3aa**.

#### Typical Procedure for [3+2] Cycloaddition by AgHMDS:


To a dried 5 mL microwave vial, KHMDS (4.0 mg, 0.020 mmol), AgOTf (5.7 mg, 0.022 mmol) and (*R*)-Fesulphos **L5** (10.1 mg, 0.022 mmol) was added in the glovebox under Ar atmosphere and sealed with a rubber septum. Dry mesitylene (1 mL) was added and the mixture was allowed to stir until all the solids have dissolved. It was then stirred at 40 °C for 1 hour and transferred to a -40 °C bath. To the catalyst mixture, Schiff base **1a** (102.1 mg, 0.40 mmol), H-HMDS (42 µL, 0.20 mmol) was transferred *via* cannula by dry mesitylene (0.9 mL) and allowed to stir for 10 minutes. Methyl acrylate **2a** (45 µL, 0.50 mmol) was then added directly to the mixture and followed by dry mesitylene (0.1 mL). The mixture was stirred at -40 °C for 18 hours. The reaction was quenched

with saturated NH<sub>4</sub>Cl (3 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 x 15 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated *in vacuo*. The crude sample was purified by preparative TLC (Et<sub>2</sub>O/MeOH: 200/1) to afford the desired product. The enantiomeric excess of the product was analysed by HPLC.


**(2*R*,3*S*,5*R*)-Methyl-5-(diethoxyphosphoryl)-2-phenylpyrrolidine-3-carboxylate (3aa):**

 colourless oil; [α]<sub>D</sub> +22 (*c* 1.00, CHCl<sub>3</sub>, 95% *ee*); **IR** (neat)  $\nu_{\text{max}}$  3326, 2983, 1738, 1453, 1234, 1053, 1029, 966, 703 cm<sup>-1</sup>; **<sup>1</sup>H-NMR** (500 MHz, CDCl<sub>3</sub>) δ 1.31 (t, *J* = 7.2 Hz, 3H), 1.33 (t, *J* = 7.2 Hz, 3H), 2.16-2.22 (m, 1H), 2.28 (br. s, 1H), 2.43-2.53 (m, 1H), 3.08 (s, 3H), 3.27 (ddd, *J* = 8.9, 8.5, 8.3 Hz, 1H), 3.39-3.44 (m, 1H), 4.15-4.26 (m, 4H), 4.45 (d, *J* = 9.2 Hz, 1H), 7.13-7.16 (m, 1H), 7.19-7.22 (m, 2H), 7.26-7.28 (m, 2H); **<sup>13</sup>C-NMR** (151 MHz, CDCl<sub>3</sub>) δ 16.7 (d, *J*<sub>P-C</sub> = 5.8 Hz), 16.7 (d, *J*<sub>P-C</sub> = 5.8 Hz), 30.1, 49.9 (d, *J*<sub>P-C</sub> = 13.9 Hz), 51.3, 54.9 (d, *J*<sub>P-C</sub> = 165.2 Hz), 62.6 (d, *J*<sub>P-C</sub> = 6.9 Hz), 63.0 (d, *J*<sub>P-C</sub> = 6.5 Hz), 65.8 (d, *J*<sub>P-C</sub> = 18.6 Hz), 124.4, 127.6, 128.1, 139.9, 172.8; **<sup>31</sup>P-NMR** (200 MHz, CDCl<sub>3</sub>) δ 26.2; **HPLC** Diacel Chiralpak AD-H column (Hexane/<sup>i</sup>PrOH: 9/1, 0.6 mL/min, 210 nm, *t*<sub>R</sub> : 23.7 min (2*R*,3*S*,5*R*), 33.2 min (2*S*,3*R*,5*S*); **DART-HRMS** calcd. for C<sub>16</sub>H<sub>25</sub>NO<sub>5</sub>P: 342.1470 [M+H]<sup>+</sup>, found: 342.1483 [M+H]<sup>+</sup>.

**(2*R*,3*S*,5*R*)-Methyl-5-(diethoxyphosphoryl)-2-(*p*-tolyl)pyrrolidine-3-carboxylate (3ba):** off-


 white solid; **mp** 73-75 °C, [α]<sub>D</sub> +28 (*c* 1.00, CHCl<sub>3</sub>, 97% *ee*); **IR** (neat)  $\nu_{\text{max}}$  2983, 1738, 1233, 1052, 1028, 965 cm<sup>-1</sup>; **<sup>1</sup>H-NMR** (500 MHz, CDCl<sub>3</sub>) δ 1.30 (t, *J* = 7.5 Hz, 3H), 1.32 (t, *J* = 7.5 Hz, 3H), 2.15-2.26 (m, 1H), 2.22 (s, 3H), 2.36 (br. s, 1H), 2.40-2.50 (m, 1H), 3.11 (s, 3H), 3.24 (ddd, *J* = 8.8, 8.3, 8.3 Hz, 1H), 3.37-3.41 (m, 1H), 4.13-4.25 (m, 4H), 4.41 (d, *J* = 9.2 Hz, 1H), 7.00 (d, *J* = 7.7 Hz, 2H), 7.14 (d, *J* = 7.7 Hz, 2H); **<sup>13</sup>C-NMR** (125 MHz, CDCl<sub>3</sub>) δ 16.6 (d, *J*<sub>P-C</sub> = 4.8 Hz), 16.7 (d, *J*<sub>P-C</sub> = 4.8 Hz), 21.1, 30.1, 49.8 (d, *J*<sub>P-C</sub> = 13.8 Hz), 51.2, 54.8 (d, *J*<sub>P-C</sub> = 167 Hz), 62.5 (d, *J*<sub>P-C</sub> = 7.3 Hz), 62.9 (d, *J*<sub>P-C</sub> = 7.1 Hz), 65.6 (d, *J*<sub>P-C</sub> = 19.3 Hz), 127.2, 128.7, 137.1, 136.8, 172.8; **<sup>31</sup>P-NMR** (243 MHz, CDCl<sub>3</sub>) δ 26.3; **HPLC** Diacel Chiralpak AD-H column (Hexane /<sup>i</sup>PrOH: 4/1, 1.0 mL/min, 210 nm, *t*<sub>R</sub> : 6.9 min (2*R*,3*S*,5*R*), 10.6 min (2*S*,3*R*,5*S*); **DART-HRMS** calcd. for C<sub>17</sub>H<sub>27</sub>NO<sub>5</sub>P: 356.1627 [M+H]<sup>+</sup>, found: 356.1627 [M+H]<sup>+</sup>.

**(2*R*,3*S*,5*R*)-Methyl-5-(diethoxyphosphoryl)-2-(*m*-tolyl)pyrrolidine-3-carboxylate (3ca):** pale

 yellow oil; [α]<sub>D</sub> +23 (*c* 1.00, CHCl<sub>3</sub>, 90% *ee*); **IR** (neat)  $\nu_{\text{max}}$  3369, 2983, 1738, 1438, 1232, 1053, 1029, 965, 789 cm<sup>-1</sup>; **<sup>1</sup>H-NMR** (500 MHz, CDCl<sub>3</sub>) δ 1.32 (t, *J* = 7.4 Hz, 3H), 1.33 (t, *J* = 7.5 Hz, 3H), 2.17-2.23 (m, 1H), 2.25 (s, 3H), 2.41-2.51 (m, 1H), 3.11 (s, 3H), 3.26 (ddd, *J* = 8.4, 8.4, 8.4 Hz, 1H), 3.39-3.43 (m, 1H), 4.15-4.27 (m, 4H), 4.41 (d, *J* = 9.3 Hz, 1H), 6.96-6.97 (m, 1H), 7.05-7.11 (m, 3H); **<sup>13</sup>C-NMR** (151 MHz, CDCl<sub>3</sub>) δ 16.7 (d, *J*<sub>P-C</sub> = 4.7 Hz), 16.7 (d, *J*<sub>P-C</sub> =


4.7 Hz), 21.5, 30.3, 49.9 (d,  $J_{P-C} = 13.6$  Hz), 51.3, 54.9 (d,  $J_{P-C} = 164.4$  Hz), 62.6 (d,  $J_{P-C} = 6.8$  Hz), 63.0 (d,  $J_{P-C} = 6.5$  Hz), 66.0 (d,  $J_{P-C} = 18.6$  Hz), 124.5, 128.0, 128.1, 128.4, 137.6, 139.8, 172.9;  $^{31}P$ -NMR (200 MHz, CDCl<sub>3</sub>)  $\delta$  26.3; HPLC Diacel Chiralpak AD-H column (Hexane/<sup>i</sup>PrOH: 4/1, 1.0 mL/min, 210 nm,  $t_R$ : 6.6 min (2*R*,3*S*,5*R*), 10.5 min (2*S*,3*R*,5*S*); DART-HRMS calcd. for C<sub>17</sub>H<sub>27</sub>NO<sub>5</sub>P: 356.1627 [M+H]<sup>+</sup>, found: 356.1613 [M+H]<sup>+</sup>.

**(2*R*,3*S*,5*R*)-Methyl-5-(diethoxyphosphoryl)-2-(*o*-tolyl)pyrrolidine-3-carboxylate (3da):** pale




yellow oil;  $[\alpha]_D +64$  (*c* 1.00, CHCl<sub>3</sub>, 93% *ee*); IR (neat)  $\nu_{max}$  3462, 3293, 2983, 1739, 1438, 1231, 1165, 1053, 1029, 966, 752 cm<sup>-1</sup>;  $^1H$ -NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  1.35 (t,  $J = 7.1$  Hz, 3H), 1.37 (t,  $J = 7.1$  Hz, 3H), 2.24-2.28 (m, 1H), 2.31 (s, 3H), 2.51-2.57 (m, 1H), 3.00 (s, 3H), 3.36 (ddd,  $J = 6.9$ , 8.5, 9.3 Hz, 1H), 3.42 (ddd,  $J = 4.7$ , 7.1, 10.8 Hz, 1H), 4.19-4.34 (m, 4H), 4.56 (d,  $J = 9.1$  Hz, 1H), 7.05-7.11 (m, 3H), 7.41-7.43 (m, 1H);  $^{13}C$ -NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  16.7 (d,  $J_{P-C} = 5.9$  Hz), 16.7 (d,  $J_{P-C} = 5.9$  Hz), 19.6, 30.2, 47.6 (d,  $J_{P-C} = 13.6$  Hz), 51.2, 54.7 (d,  $J_{P-C} = 166.4$  Hz), 62.6 (d,  $J_{P-C} = 7.0$  Hz), 63.0 (d,  $J_{P-C} = 21.7$  Hz), 63.2 (d,  $J_{P-C} = 6.5$  Hz), 125.9, 126.3, 127.4, 129.9, 135.8, 137.3, 173.1;  $^{31}P$ -NMR (200 MHz, CDCl<sub>3</sub>)  $\delta$  26.0; HPLC Diacel Chiralpak AD-H column (Hexane/<sup>i</sup>PrOH: 4/1, 1.0 mL/min, 210 nm,  $t_R$ : 5.6 min (2*R*,3*S*,5*R*), 6.8 min (2*S*,3*R*,5*S*); DART-HRMS calcd. for C<sub>17</sub>H<sub>27</sub>NO<sub>5</sub>P: 356.1627 [M+H]<sup>+</sup>, found: 356.16211 [M+H]<sup>+</sup>.

**(2*R*,3*S*,5*R*)-Methyl-5-(diethoxyphosphoryl)-2-(4-methoxy-phenyl)-pyrrolidine-3-carboxylate**



(3ea): colourless oil;  $[\alpha]_D +22$  (*c* 1.00, CHCl<sub>3</sub>, 99% *ee*); IR (neat)  $\nu_{max}$  3364, 2982, 1737, 1515, 1250, 1032, 967 cm<sup>-1</sup>;  $^1H$ -NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  1.35 (t,  $J = 7.1$  Hz, 3H), 1.37 (t,  $J = 7.1$  Hz, 3H), 2.19-2.24 (m, 1H), 2.29 (br. s, 1H), 2.46-2.54 (m, 1H), 3.17 (s, 3H), 3.27 (ddd,  $J = 8.6$ , 8.6, 8.6 Hz, 1H), 3.44 (ddd,  $J = 4.8$ , 6.7, 11.1 Hz, 1H), 4.18-4.28 (m, 4H), 4.46 (d,  $J = 9.2$  Hz, 1H), 6.8 (d,  $J = 8.4$  Hz, 2H), 7.23 (d,  $J = 8.7$  Hz, 2H);  $^{13}C$ -NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  16.7 (d,  $J_{P-C} = 5.8$  Hz), 16.8 (d,  $J_{P-C} = 5.8$  Hz), 30.1, 50.0 (d,  $J_{P-C} = 13.9$  Hz), 51.4, 54.9 (d,  $J_{P-C} = 166.3$  Hz), 55.4, 62.6 (d,  $J_{P-C} = 7.0$  Hz), 63.0 (d,  $J_{P-C} = 6.6$  Hz), 65.4 (d,  $J_{P-C} = 19.5$  Hz), 113.5, 128.6, 132.1, 159.2, 172.9;  $^{31}P$ -NMR (243 MHz, CDCl<sub>3</sub>)  $\delta$  26.3; HPLC Diacel Chiralpak AD-H column (Hexane/<sup>i</sup>PrOH: 4/1, 1.0 mL/min, 210 nm,  $t_R$ : 9.7 min (2*R*,3*S*,5*R*), 14.9 min (2*S*,3*R*,5*S*); DART-HRMS calcd. for C<sub>17</sub>H<sub>27</sub>NO<sub>6</sub>P: 372.1576 [M+H]<sup>+</sup>, found: 372.1563 [M+H]<sup>+</sup>.


**(2*R*,3*S*,5*R*)-Methyl-5-(diethoxyphosphoryl)-2-(4-fluorophenyl)-pyrrolidine-3-carboxylate**



(3fa): white solid; mp 83-85 °C,  $[\alpha]_D +29$  (*c* 0.50, CHCl<sub>3</sub>, 99% *ee*); IR (neat)  $\nu_{max}$  2983, 1731, 1510, 1231, 1028, 967 cm<sup>-1</sup>;  $^1H$ -NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  1.38 (t,  $J = 7.1$  Hz, 3H), 1.40 (t,  $J = 7.1$  Hz, 3H), 2.22-2.28 (m, 1H), 2.41 (br. s, 1H), 2.49-2.57 (m, 1H), 3.20 (s, 3H), 3.33 (ddd,  $J = 8.4$ , 8.9, 8.9 Hz, 1H), 3.44-3.54 (m, 1H), 4.21-4.32 (m, 4H), 4.54 (d,  $J = 9.3$  Hz, 1H),


6.95-6.99 (m, 2H), 7.32-7.35 (m, 2H); **<sup>13</sup>C-NMR** (125 MHz, CDCl<sub>3</sub>) δ 16.7 (d, J<sub>P-C</sub> = 5.3 Hz), 16.7 (d, J<sub>P-C</sub> = 5.3 Hz), 29.8, 49.9 (d, J<sub>P-C</sub> = 14.0 Hz), 51.4, 54.8 (d, J<sub>P-C</sub> = 168.9 Hz), 62.5 (d, J<sub>P-C</sub> = 6.9 Hz), 63.0 (d, J<sub>P-C</sub> = 6.6 Hz), 64.8 (d, J<sub>P-C</sub> = 18.9 Hz), 114.9 (d, J<sub>F-C</sub> = 21.6 Hz), 129.1 (d, J<sub>F-C</sub> = 8.0 Hz), 136.0 (d, J<sub>F-C</sub> = 2.5 Hz), 162.3 (d, J<sub>F-C</sub> = 246.6 Hz), 172.5; **<sup>31</sup>P-NMR** (200 MHz, CDCl<sub>3</sub>) δ 26.0; **HPLC** Diacel Chiraldak AD-H column (Hexane/<sup>i</sup>PrOH: 4/1, 1.0 mL/min, 210 nm, t<sub>R</sub>: 6.9 min (2R,3S,5R), 12.4 min (2S,3R,5S); **DART-HRMS** calcd. for C<sub>16</sub>H<sub>24</sub>FNO<sub>5</sub>P: 360.1376 [M+H]<sup>+</sup>, found: 360.1367 [M+H]<sup>+</sup>.

### (2*R*,3*S*,5*R*)-Methyl-5-(diethoxyphosphoryl)-2-(4-bromophenyl)-pyrrolidine-3-carboxylate




**(3ga)**: white solid; **mp** 133-135 °C, [α]<sub>D</sub> +23 (c 1.00, CHCl<sub>3</sub>, 99% ee); **IR** (neat) ν<sub>max</sub> 3299, 2981, 1729, 1229, 1048, 1025, 970 cm<sup>-1</sup>; **<sup>1</sup>H-NMR** (400 MHz, CDCl<sub>3</sub>) δ 1.36 (t, J = 6.8 Hz, 3H), 1.38 (t, J = 6.8 Hz, 3H), 2.20-2.27 (m, 1H), 2.36 (br. s, 1H), 2.45-2.55 (m, 1H), 3.20 (s, 3H), 3.35 (ddd, J = 8.7, 8.7, 8.7 Hz, 1H), 3.45-3.50 (m, 1H), 4.18-4.31 (m, 4H), 4.49 (d, J = 9.3 Hz, 1H), 7.23 (d, J = 8.2 Hz, 1H), 7.39 (d, J = 8.2 Hz, 1H); **<sup>13</sup>C-NMR** (101 MHz, CDCl<sub>3</sub>) δ 16.7 (d, J<sub>P-C</sub> = 5.1 Hz), 16.7 (d, J<sub>P-C</sub> = 5.1 Hz), 29.7, 49.7 (d, J<sub>P-C</sub> = 14.3 Hz), 51.4, 54.7 (d, J<sub>P-C</sub> = 170.3 Hz), 62.5 (d, J<sub>P-C</sub> = 7.7 Hz), 63.0 (d, J<sub>P-C</sub> = 6.6 Hz), 64.6 (d, J<sub>P-C</sub> = 19.3 Hz), 121.5, 129.2, 131.1, 139.4, 172.34; **<sup>31</sup>P-NMR** (243 MHz, CDCl<sub>3</sub>) δ 26.0; **HPLC** Diacel Chiraldak AD-H column (Hexane/<sup>i</sup>PrOH: 4/1, 1.0 mL/min, 210 nm, t<sub>R</sub>: 7.0 min (2R,3S,5R), 13.4 min (2S,3R,5S); **DART-HRMS** calcd. for C<sub>16</sub>H<sub>24</sub>BrNO<sub>5</sub>P: 420.0576 [M+H]<sup>+</sup>, found: 420.0579 [M+H]<sup>+</sup>.

### (2*R*,3*S*,5*R*)-Methyl-5-(diethoxyphosphoryl)-2-(4-(trifluoro-methyl)phenyl)pyrrolidine-3-carboxylate (3ha)



**(3ha)**: colourless oil; [α]<sub>D</sub> +11 (c 1.00, CHCl<sub>3</sub>, 98% ee); **IR** (neat) ν<sub>max</sub> 3322, 2986, 1739, 1327, 1234, 1165, 1122, 1066, 1054, 1029, 965, 850 cm<sup>-1</sup>; **<sup>1</sup>H-NMR** (500 MHz, CDCl<sub>3</sub>) δ 1.34 (t, J = 7.3 Hz, 3H), 1.36 (t, J = 7.3 Hz, 3H), 2.21-2.26 (m, 1H), 2.43 (br. s, 1H), 2.45-2.55 (m, 1H), 3.13 (s, 3H), 3.35 (ddd, J = 8.3, 8.7, 9.0 Hz, 1H), 3.47-3.51 (m, 1H), 4.17-4.27 (m, 4H), 4.57 (d, J = 9.3 Hz, 1H), 7.45-7.51 (m, 4H); **<sup>13</sup>C-NMR** (151 MHz, CDCl<sub>3</sub>) δ 16.7 (d, J<sub>P-C</sub> = 5.7 Hz), 16.7 (d, J<sub>P-C</sub> = 5.7 Hz), 29.7, 50.0 (d, J<sub>P-C</sub> = 13.9 Hz), 51.4, 54.8 (d, J<sub>P-C</sub> = 169.1 Hz), 62.6 (d, J<sub>P-C</sub> = 6.9 Hz), 63.1 (d, J<sub>P-C</sub> = 6.6 Hz), 64.7 (d, J<sub>P-C</sub> = 18.7 Hz), 124.3 (d, J<sub>F-C</sub> = 271.8 Hz), 124.9 (d, J<sub>F-C</sub> = 3.0 Hz), 128.0, 130.0 (d, J<sub>F-C</sub> = 32.5 Hz), 144.6, 172.2; **<sup>31</sup>P-NMR** (200 MHz, CDCl<sub>3</sub>) δ 25.9; **HPLC** Diacel Chiraldak AD-H column (Hexane/<sup>i</sup>PrOH: 4/1, 1.0 mL/min, 210 nm, t<sub>R</sub>: 6.2 min (2R,3S,5R), 9.1 min (2S,3R,5S); **DART-HRMS** calcd. for C<sub>17</sub>H<sub>24</sub>F<sub>3</sub>NO<sub>5</sub>P: 410.1344 [M+H]<sup>+</sup>, found: 410.1364 [M+H]<sup>+</sup>.


### (2*R*,3*S*,5*R*)-Methyl-5-(diethoxyphosphoryl)-2-(naphthalen-2-yl)pyrrolidine-3-carboxylate



**(3ia)**: yellow oil; [α]<sub>D</sub> +27 (c 1.00, CHCl<sub>3</sub>, 88% ee); **IR** (neat) ν<sub>max</sub> 3324, 2982, 1737, 1438, 1234, 1050, 1028, 965, 823, 749 cm<sup>-1</sup>; **<sup>1</sup>H-**


**NMR** (600 MHz, CDCl<sub>3</sub>) δ 1.38 (t, *J* = 7.1 Hz, 3H), 1.40 (t, *J* = 7.1 Hz, 3H), 2.26-2.31 (m, 1H), 2.54-2.62 (m, 1H), 3.02 (s, 3H), 3.40 (ddd, *J* = 8.6, 8.6, 8.6 Hz, 1H), 3.52 (ddd, *J* = 4.8, 6.9, 11.0 Hz, 1H), 4.22-4.35 (m, 4H), 4.65 (d, *J* = 9.2 Hz, 1H), 7.40-7.44 (m, 3H), 7.73 (d, *J* = 8.6 Hz, 1H), 7.76-7.78 (m, 2H), 7.79 (s, 1H); **<sup>13</sup>C-NMR** (151 MHz, CDCl<sub>3</sub>) δ 16.7 (d, *J<sub>P-C</sub>* = 6.0 Hz), 16.8 (d, *J<sub>P-C</sub>* = 6.0 Hz), 30.2, 49.9 (d, *J<sub>P-C</sub>* = 13.7 Hz), 51.3, 55.0 (d, *J<sub>P-C</sub>* = 167.0 Hz), 62.6 (d, *J<sub>P-C</sub>* = 7.0 Hz), 63.0 (d, *J<sub>P-C</sub>* = 6.6 Hz), 65.9 (d, *J<sub>P-C</sub>* = 19.5 Hz), 125.7, 125.9, 126.1, 126.2, 127.6, 127.7, 128.1, 133.1, 133.2, 137.5, 172.8; **<sup>31</sup>P-NMR** (200 MHz, CDCl<sub>3</sub>) δ 26.2; **HPLC** Diacel Chiralpak AD-H column (Hexane/<sup>i</sup>PrOH: 4/1, 1.0 mL/min, 210 nm, *t<sub>R</sub>*: 10.1 min (2*R*,3*S*,5*R*), 20.7 min (2*S*,3*R*,5*S*); **DART-HRMS** calcd. for C<sub>20</sub>H<sub>27</sub>NO<sub>5</sub>P: 392.1627 [M+H]<sup>+</sup>, found: 392.1614 [M+H]<sup>+</sup>.

### (2*R*,3*S*,5*R*)-Methyl-5-(diethoxyphosphoryl)-2-(naphthalen-1-yl)pyrrolidine-3-carboxylate




**(3ja)**: yellow oil;  $[\alpha]_D +117$  (*c* 1.00, CHCl<sub>3</sub>, 91% *ee*); **IR** (neat)  $\nu_{\max}$  3280, 2983, 1737, 1437, 1233, 1047, 1028, 967, 793 cm<sup>-1</sup>; **<sup>1</sup>H-NMR** (600 MHz, CDCl<sub>3</sub>) δ 1.36 (t, *J* = 7.1 Hz, 3H), 1.38 (t, *J* = 7.1 Hz, 3H), 2.28-2.33 (m, 1H), 2.48 (br. s, 1H), 2.55-2.64 (m, 1H), 2.69 (s, 3H), 3.51-3.55 (m, 2H), 4.21-4.35 (m, 4H), 5.16 (d, *J* = 8.9 Hz, 1H), 7.38 (dd, *J* = 7.2, 8.2 Hz, 1H), 7.41 (dd, *J* = 7.2, 8.1 Hz, 1H), 7.46 (dd, *J* = 6.6, 8.6 Hz, 1H), 7.69 (d, *J* = 8.3 Hz, 1H), 7.71 (d, *J* = 7.3 Hz, 1H), 7.78 (d, *J* = 8.2 Hz, 1H), 7.96 (d, *J* = 8.5 Hz, 1H); **<sup>13</sup>C-NMR** (151 MHz, CDCl<sub>3</sub>) δ 16.8 (d, *J<sub>P-C</sub>* = 7.7 Hz), 16.8 (d, *J<sub>P-C</sub>* = 7.7 Hz), 30.3, 48.8 (d, *J<sub>P-C</sub>* = 13.3 Hz), 51.0, 54.7 (d, *J<sub>P-C</sub>* = 167.0 Hz), 62.2 (d, *J<sub>P-C</sub>* = 21.0 Hz), 62.7 (d, *J<sub>P-C</sub>* = 7.0 Hz), 63.3 (d, *J<sub>P-C</sub>* = 6.4 Hz), 123.2, 124.4, 125.4, 125.5, 126.0, 128.1, 128.9, 131.4, 131.8, 133.5, 135.1, 173.0; **<sup>31</sup>P-NMR** (243 MHz, CDCl<sub>3</sub>) δ 26.0; **HPLC** Diacel Chiralpak OD-H column (Hexane/<sup>i</sup>PrOH: 4/1, 1.0 mL/min, 210 nm, *t<sub>R</sub>*: 10.7 min (2*S*,3*R*,5*S*), 18.3 min (2*R*,3*S*,5*R*); **DART-HRMS** calcd. for C<sub>20</sub>H<sub>27</sub>NO<sub>5</sub>P: 392.1627 [M+H]<sup>+</sup>, found: 392.1618 [M+H]<sup>+</sup>.

### (2*R*,3*S*,5*R*)-Methyl-5-(diethoxyphosphoryl)-2-(furan-2-yl)pyrrolidine-3-carboxylate (3ka)




**(3ka)**: yellow oil;  $[\alpha]_D -6$  (*c* 1.00, CHCl<sub>3</sub>, 97% *ee*); **IR** (neat)  $\nu_{\max}$  3327, 2984, 1739, 1439, 1369, 1235, 1027, 965, 743 cm<sup>-1</sup>; **<sup>1</sup>H-NMR** (600 MHz, CDCl<sub>3</sub>) δ 1.31 (t, *J* = 7.1 Hz, 3H), 1.32 (t, *J* = 7.1 Hz, 3H), 2.20-2.25 (m, 1H), 2.38 (br. s, 1H), 2.43-2.51 (m, 1H), 3.22 (ddd, *J* = 8.9, 8.9, 7.7 Hz, 1H), 3.40 (s, 3H), 4.14-4.19 (m, 4H), 4.52 (d, *J* = 8.8 Hz, 1H), 6.24-6.26 (m, 2H), 7.25-7.27 (m, 1H); **<sup>13</sup>C-NMR** (151 MHz, CDCl<sub>3</sub>) δ 16.6 (d, *J<sub>P-C</sub>* = 5.8 Hz), 30.2, 48.7 (d, *J<sub>P-C</sub>* = 13.1 Hz), 51.9, 54.6 (d, *J<sub>P-C</sub>* = 164.1 Hz), 59.6 (d, *J<sub>P-C</sub>* = 17.6 Hz), 62.7 (d, *J<sub>P-C</sub>* = 6.8 Hz), 62.9 (d, *J<sub>P-C</sub>* = 6.8 Hz), 107.4, 110.4, 141.9, 153.3, 172.4; **<sup>31</sup>P-NMR** (243 MHz, CDCl<sub>3</sub>) δ 26.0; **HPLC** Diacel Chiralpak AD-H column (Hexane/<sup>i</sup>PrOH: 4/1, 1.0 mL/min, 210 nm, *t<sub>R</sub>*: 16.0 min (2*S*,3*R*,5*S*), 19.6 min (2*R*,3*S*,5*R*); **DART-HRMS** calcd. for C<sub>14</sub>H<sub>23</sub>NO<sub>6</sub>P: 332.1263 [M+H]<sup>+</sup>, found: 332.1279 [M+H]<sup>+</sup>.


**(2*R*,3*S*,5*R*)-Methyl-5-(diethoxyphosphoryl)-2-((*E*)-styryl)-pyrrolidine-3-carboxylate (3la):**


 yellow oil;  $[\alpha]_D$  -11 (*c* 0.50, CHCl<sub>3</sub>, 96% *ee*); **IR** (neat)  $\nu_{max}$  2983, 1736, 1439, 1370, 1232, 1027, 965, 748 cm<sup>-1</sup>; **<sup>1</sup>H-NMR** (600 MHz, CDCl<sub>3</sub>)  $\delta$  1.29 (t, *J* = 7.1 Hz, 3H), 1.30 (t, *J* = 7.1 Hz, 3H), 2.18 (br. s, 1H), 2.19-2.24 (m, 1H), 2.34-2.42 (m, 1H), 3.14 (ddd, *J* = 8.7, 8.7, 7.8 Hz, 1H), 3.52 (ddd, *J* = 6.9, 6.9, 10.9 Hz, 1H), 3.52 (s, 3H), 3.98 (dd, *J* = 7.7, 8.7 Hz, 1H), 4.13-4.17 (m, 4H), 6.06 (dd, *J* = 7.8, 15.8 Hz, 1H), 6.49 (d, *J* = 15.8 Hz, 1H), 7.14-7.16 (m, 1H), 7.20-7.23 (m, 2H), 7.24-7.26 (m, 2H); **<sup>13</sup>C-NMR** (151 MHz, CDCl<sub>3</sub>)  $\delta$  16.7 (d, *J<sub>P-C</sub>* = 5.6 Hz), 30.6, 49.1 (d, *J<sub>P-C</sub>* = 12.3 Hz), 51.9, 54.8 (d, *J<sub>P-C</sub>* = 162.6 Hz), 62.7 (d, *J<sub>P-C</sub>* = 7.0 Hz), 62.9 (d, *J<sub>P-C</sub>* = 6.8 Hz), 64.3 (d, *J<sub>P-C</sub>* = 16.1 Hz), 126.7, 127.5, 127.9, 128.7, 132.5, 136.9, 173.0; **<sup>31</sup>P-NMR** (243 MHz, CDCl<sub>3</sub>)  $\delta$  26.5; **HPLC** Diacel Chiralpak AD-H column (Hexane/<sup>i</sup>PrOH: 4/1, 1.0 mL/min, 210 nm, *t<sub>R</sub>*: 14.7 min (2*S*,3*R*,5*S*), 22.8 min (2*R*,3*S*,5*R*); **DART-HRMS** calcd. for C<sub>18</sub>H<sub>27</sub>NO<sub>5</sub>P: 368.1627 [M+H]<sup>+</sup>, found: 368.1642 [M+H]<sup>+</sup>.

**Diethyl ((2*R*,4*S*,5*R*)-4-(morpholine-4-carbonyl)-5-phenylpyrrolidin-2-yl)phosphonate (3ab):**



 yellow oil;  $[\alpha]_D$  -26 (*c* 1.00, CHCl<sub>3</sub>, 88% *ee*); **IR** (neat)  $\nu_{max}$  3448, 2980, 2907, 2859, 1643, 1455, 1441, 1240, 1116, 1027, 968, 702 cm<sup>-1</sup>; **<sup>1</sup>H-NMR** (600 MHz, CDCl<sub>3</sub>)  $\delta$  1.32 (t, *J* = 6.4 Hz, 6H), 2.14-2.19 (m, 1H), 2.53 (br. s, 1H), 2.70-2.78 (m, 2H), 2.90-2.93 (m, 1H), 2.98-3.01 (m, 1H), 3.11-3.15 (m, 1H), 3.18-3.24 (m, 2H), 3.34-3.45 (m, 4H), 4.15-4.24 (m, 4H), 4.26 (d, *J* = 8.9 Hz, 1H), 7.18-7.30 (m, 5H); **<sup>13</sup>C-NMR** (151 MHz, CDCl<sub>3</sub>)  $\delta$  16.7 (d, *J<sub>P-C</sub>* = 5.0 Hz), 16.7 (d, *J<sub>P-C</sub>* = 5.0 Hz), 31.6, 41.9, 45.7 (d, *J<sub>P-C</sub>* = 13.2 Hz), 45.8, 55.0 (d, *J<sub>P-C</sub>* = 163.4 Hz), 62.9 (d, *J<sub>P-C</sub>* = 10.6 Hz), 62.9 (d, *J<sub>P-C</sub>* = 9.1 Hz), 64.0, 66.1, 66.4, 67.4 (d, *J<sub>P-C</sub>* = 20.2 Hz), 128.1, 128.3, 128.4, 139.1, 170.6; **<sup>31</sup>P-NMR** (243 MHz, CDCl<sub>3</sub>)  $\delta$  26.7; **HPLC** Diacel Chiralpak AD-H column (Hexane/<sup>i</sup>PrOH: 4/1, 1.0 mL/min, 210 nm, *t<sub>R</sub>*: 11.6 min (2*S*,3*R*,5*S*), 13.3 min (2*R*,3*S*,5*R*); **DART-HRMS** calcd. for C<sub>19</sub>H<sub>30</sub>N<sub>2</sub>O<sub>5</sub>P: 397.1892 [M+H]<sup>+</sup>, found: 397.1877 [M+H]<sup>+</sup>.

**Diethyl ((2*R*,4*S*,5*R*)-4-(dimethylcarbamoyl)-5-phenylpyrrolidin-2-yl)phosphonate (3ac):**


 yellow oil;  $[\alpha]_D$  -13 (*c* 0.50, CHCl<sub>3</sub>, 85% *ee*); **IR** (neat)  $\nu_{max}$  3421, 2982, 1641, 1233, 1051, 1029, 965, 702 cm<sup>-1</sup>; **<sup>1</sup>H-NMR** (600 MHz, CDCl<sub>3</sub>)  $\delta$  1.32 (t, *J* = 7.1 Hz, 6H), 2.11-2.16 (m, 1H), 2.44 (s, 3H), 2.64 (s, 3H), 2.65-2.72 (m, 1H), 3.35-3.39 (m, 1H), 3.49 (dd, *J* = 8.2, 8.6 Hz, 1H), 4.13-4.24 (m, 4H), 4.34 (d, *J* = 9.0 Hz, 1H), 7.15-7.27 (m, 5H); **<sup>13</sup>C-NMR** (151 MHz, CDCl<sub>3</sub>)  $\delta$  16.7 (d, *J<sub>P-C</sub>* = 5.2 Hz), 16.7 (d, *J<sub>P-C</sub>* = 5.2 Hz), 31.4, 35.4, 37.2, 46.4 (d, *J<sub>P-C</sub>* = 13.4 Hz), 55.0 (d, *J<sub>P-C</sub>* = 163.4 Hz), 55.3 (d, *J<sub>P-C</sub>* = 13.1 Hz), 62.8 (d, *J<sub>P-C</sub>* = 8.0 Hz), 62.9 (d, *J<sub>P-C</sub>* = 7.9 Hz), 64.0, 66.8 (d, *J<sub>P-C</sub>* = 19.5 Hz), 127.7, 128.0, 128.1, 139.5, 171.6; **<sup>31</sup>P-NMR** (243 MHz, CDCl<sub>3</sub>)  $\delta$  26.6; **HPLC** Diacel Chiralpak AD-H column (Hexane/<sup>i</sup>PrOH: 4/1, 1.0 mL/min, 210 nm, *t<sub>R</sub>*: 8.7 min (2*S*,3*R*,5*S*),


10.1 min (*2R,3S,5R*); **DART-HRMS** calcd. for C<sub>17</sub>H<sub>28</sub>N<sub>2</sub>O<sub>4</sub>P: 355.1787 [M+H]<sup>+</sup>, found: 355.1774 [M+H]<sup>+</sup>.

### (*2R,3S,5R*)-Methyl-5-(diethoxyphosphoryl)-3-methyl-2-phenyl-pyrrolidine-3-carboxylate



**(3ad)**: white solid; **mp** 86-88 °C,  $[\alpha]_D$  -24 (*c* 0.50, CHCl<sub>3</sub>, 98% *ee*); **IR** (neat)  $\nu_{max}$  3309, 2990, 1721, 1456, 1232, 1027, 963 cm<sup>-1</sup>; **<sup>1</sup>H-NMR** (600 MHz, CDCl<sub>3</sub>)  $\delta$  1.32 (t, *J* = 7.2 Hz, 3H), 1.33 (t, *J* = 7.2 Hz, 3H), 1.39 (s, 3H), 1.82 (ddd, *J* = 6.7, 12.9 Hz, 1H), 1.46 (br. s, 1H), 2.80-2.87 (m, 1H), 3.06 (s, 3H), 3.51 (ddd, *J* = 5.1, 6.7, 11.3 Hz, 1H), 3.95 (s, 1H), 4.16-4.27 (m, 4H), 7.14-7.17 (m, 1H), 7.19-7.22 (m, 2H), 7.25-7.26 (m, 2H); **<sup>13</sup>C-NMR** (151 MHz, CDCl<sub>3</sub>)  $\delta$  16.7 (d, *J<sub>P-C</sub>* = 4.8 Hz), 16.7 (d, *J<sub>P-C</sub>* = 4.8 Hz), 24.3, 38.1, 51.5, 53.9 (d, *J<sub>P-C</sub>* = 167.0 Hz), 55.3 (d, *J<sub>P-C</sub>* = 13.1 Hz), 62.6 (d, *J<sub>P-C</sub>* = 6.9 Hz), 62.9 (d, *J<sub>P-C</sub>* = 6.7 Hz), 74.6 (d, *J<sub>P-C</sub>* = 18.2 Hz), 127.3, 127.8, 128.0, 139.9, 174.7; **<sup>31</sup>P-NMR** (243 MHz, CDCl<sub>3</sub>)  $\delta$  26.5; **HPLC** Diacel Chiralpak AD-H column (Hexane/<sup>i</sup>PrOH: 4/1, 1.0 mL/min, 210 nm, *t<sub>R</sub>* : 6.4 min (*2S,3R,5S*), 7.4 min (*2R,3S,5R*)); **DART-HRMS** calcd. for C<sub>17</sub>H<sub>27</sub>NO<sub>5</sub>P: 356.1627 [M+H]<sup>+</sup>, found: 356.1611 [M+H]<sup>+</sup>.

### Methyl (*2S,3S,5R*)-5-(diethoxyphosphoryl)-3-(2-methoxy-2-oxoethyl)-2-phenylpyrrolidine-3-carboxylate (3ae)





**(3ae)**: colourless oil; **mp** °C,  $[\alpha]_D$  -19 (*c* 0.25, CHCl<sub>3</sub>, 93% *ee*); **IR** (neat)  $\nu_{max}$  3312, 2994, 1722, 1699, 1521, 1027 cm<sup>-1</sup>; **<sup>1</sup>H-NMR** (600 MHz, CDCl<sub>3</sub>)  $\delta$  1.33 (m, 6H), 1.77 (br. s, 3H), 2.11-2.15 (m, 1H), 2.59 (d<sub>AB</sub>, *J<sub>AB</sub>* 17.0Hz, 1H), 3.04-3.38 (m, 4H), 3.43-3.51 (m, 1H), 3.64 (s, 3H), 3.99 (s, 1H), 4.18-4.35 (m, 4H), 7.24-7.29 (m, 5H); **<sup>13</sup>C-NMR** (151 MHz, CDCl<sub>3</sub>)  $\delta$  16.7 (t, *J<sub>P-C</sub>* = 5.9 Hz), 36.0, 41.1, 51.8 (d, *J<sub>P-C</sub>* = 23.0 Hz), 53.8 (d, *J<sub>P-C</sub>* = 166.8 Hz), 56.8 (d, *J<sub>P-C</sub>* = 6.8 Hz), 62.5 (d, *J<sub>P-C</sub>* = 7.1 Hz), 63.1 (d, *J<sub>P-C</sub>* = 6.7 Hz), 72.9, 73.1, 127.3, 128.1, 128.2, 138.3, 171.53, 172.9; **<sup>31</sup>P-NMR** (200 MHz, CDCl<sub>3</sub>)  $\delta$  26.0; **HPLC** Diacel Chiralpak AD-H column (Hexane/<sup>i</sup>PrOH: 4/1, 1.0 mL/min, 210 nm, *t<sub>R</sub>* : 7.3 min (*2R,3S,5R*), 11.1 min (*2S,3R,5S*)); **DART-HRMS** calcd. for C<sub>19</sub>H<sub>29</sub>NO<sub>7</sub>P: 414.1660 [M+H]<sup>+</sup>, found: 414.1682 [M+H]<sup>+</sup>.


### Reference

- Mancheno, O. G.; Priego, J.; Cabrera, S.; Arrayás, R. G.; Llamas, T.; Caretero, J. C. *J. Org. Chem.* **2003**, *68*, 3679.
- Davidson, S. K.; Philips, G. W.; Martin, S. F. *Org. Synth.* **1993**, *8*, 451.
- The data have been deposited with the Cambridge Crystallographic Data Centre as CCDC 1409067. Copies of the data can be obtained, free of charge, on application to the Director, CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: +44(0)12238336033 or deposit@ccdc.cam.ac.uk). As the Flack parameter of the data was 0.95(14), the actual structure of the product is the opposite enantiomer of the structure in the analysis.


### Compound 3aa $^1\text{H}$ NMR




### Compound 3aa $^{31}\text{P}$ NMR




### Compound 3ba $^1\text{H}$ NMR




**Compound 3ba  $^{13}\text{C}$  NMR**




**Compound 3ba  $^{31}\text{P}$  NMR**




### Compound 3ca $^1\text{H}$ NMR




### Compound 3ca $^{13}\text{C}$ NMR




**Compound 3ca  $^{31}\text{P}$  NMR**




**Compound 3da  $^1\text{H}$  NMR**




**Compound 3da  $^{13}\text{C}$  NMR**




**Compound 3da  $^{31}\text{P}$  NMR**




### Compound 3ea $^1\text{H}$ NMR




### Compound 3ea $^{13}\text{C}$ NMR




**Compound 3ea  $^{31}\text{P}$  NMR**




**Compound 3fa  $^1\text{H}$  NMR**




**Compound 3fa  $^{13}\text{C}$  NMR**




**Compound 3fa  $^{31}\text{P}$  NMR**




**Compound 3ga  $^1\text{H}$  NMR**




**Compound 3ga  $^{13}\text{C}$  NMR**




**Compound 3ga  $^{31}\text{P}$  NMR**




**Compound 3ha  $^1\text{H}$  NMR**




**Compound 3ha  $^{13}\text{C}$  NMR**




**Compound 3ha  $^{31}\text{P}$  NMR**




### Compound 3ia $^1\text{H}$ NMR




### Compound 3ia $^{13}\text{C}$ NMR




**Compound 3ia  $^{31}\text{P}$  NMR**




**Compound 3ja  $^1\text{H}$  NMR**




**Compound 3ja  $^{13}\text{C}$  NMR**




**Compound 3ja  $^{31}\text{P}$  NMR**




### Compound 3ka $^1\text{H}$ NMR




### Compound 3ka $^{13}\text{C}$ NMR




**Compound 3ka  $^{31}\text{P}$  NMR**




**Compound 3la  $^1\text{H}$  NMR**





**Compound 3la  $^{13}\text{C}$  NMR**




**Compound 3la  $^{31}\text{P}$  NMR**




### Compound 3ab $^1\text{H}$ NMR




**Compound 3ab  $^{31}\text{P}$  NMR**




**Compound 3ac  $^1\text{H}$  NMR**




**Compound 3ac  $^{13}\text{C}$  NMR**




**Compound 3ac  $^{31}\text{P}$  NMR**




### **Compound 3ad $^1\text{H}$ NMR**




### Compound 3ad $^{13}\text{C}$ NMR




**Compound 3ad  $^{31}\text{P}$  NMR**




**Compound 3ae  $^1\text{H}$  NMR**



**Compound 3ae  $^{13}\text{C}$  NMR**




**Compound 3ae  $^{31}\text{P}$  NMR**




### Compound 3aa HPLC (Racemic)

mAU




### Compound 3aa HPLC Silver


mAU




### Compound 3aa HPLC Copper




### Compound 3ba HPLC (Racemic)




### Compound 3ba HPLC Silver




### Compound 3ba HPLC Copper




### Compound 3ca HPLC (Racemic)




### Compound 3ca HPLC Silver




### Compound 3ca HPLC Copper




### Compound 3da HPLC (Racemic)




### Compound 3da HPLC Silver




### Compound 3da HPLC Copper




### Compound 3ea HPLC (Racemic)




### Compound 3ea HPLC Silver




### Compound 3ea HPLC Copper




### Compound 3fa HPLC (Racemic)




### Compound 3fa HPLC Silver




### Compound 3fa HPLC Copper




### Compound 3ga HPLC (Racemic)




### Compound 3ga HPLC Silver




### Compound 3ga HPLC Copper




### Compound 3ha HPLC (Racemic)




### Compound 3ha HPLC




### Compound 3ia HPLC (Racemic)




### Compound 3ia HPLC Silver




### Compound 3ia HPLC Copper




### Compound 3ja HPLC (Racemic)




### Compound 3ja HPLC Silver




### Compound 3ja HPLC Copper




### Compound 3ka HPLC (Racemic)




### Compound 3ka HPLC Copper




### Compound 3la HPLC (Racemic)




### Compound 3la HPLC




### Compound 3ab HPLC (Racemic)




### Compound 3ab HPLC Silver




### Compound 3ab HPLC Copper




### Compound 3ac HPLC (Racemic)




### Compound 3ac HPLC Silver




### Compound 3ac HPLC Copper




### Compound 3ad HPLC (Racemic)



### Compound 3ad HPLC Silver




### Compound 3ad HPLC Copper



### Compound 3ae HPLC (racemic)

m AU




Peak Table

Peak#	Ret. Time	Area	Height	Area%
1	7.088	17821874	1492184	49.915
2	10.584	17882741	975796	50.085
Total		35704615	2467980	100.000

### Compound 3ae HPLC Silver

m AU



Peak Table

Peak#	Ret. Time	Area	Height	Area%
1	7.347	1036656	60962	3.645
2	11.127	27399973	780236	96.355
Total		28436629	841198	100.000